FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-02-23

Price

$14.36

+0.14%

Score6.2Priority

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.3xvs 20d avg

Analysis

FOLD is currently trading as a high-probability merger arbitrage play, pinned at $14.36 against a definitive $14.50 all-cash acquisition offer from BioMarin (BMRN). The 'Quiet Storm' and 'Steady Climb' signals, combined with an annualized volatility of just 1.7%, confirm that the market has effectively priced in the deal's completion with minimal regulatory risk. In the current 'Caution' macro regime characterized by trade war headlines and market volatility, FOLD acts as a defensive 'Alpha Male' by decoupling from the broader tape and offering a stable, albeit capped, yield.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUE

Key Takeaways

**Thesis:** Pure merger arbitrage. The stock is tethered to the $14.50 deal price, offering a ~1% gross spread pending the Q2 2026 close.
**Macro Role:** Acts as an 'Institutional Safe Haven' in a volatile Trade War backdrop; the +1.6% relative strength vs. SPY is a function of its zero-beta nature, not organic growth.
**Risk:** Regulatory intervention (FTC) is the only structural threat, though the tight spread suggests the market views this as a 'done deal'.

← Back to 2026-02-23 View Full FOLD History →Yahoo Finance &nearr;